ATLANTA, GA – – (Businesswire – September 24, 2019) – – Holzer & Holzer, LLC is investigating whether certain statements made by Abeona Therapeutics Inc. (“Abeona Therapeutics” or the “Company”) (NASDAQ: ABEO) complied with federal securities laws. On September 23, 2019, Abeona Therapeutics announced that it received a clinical hold letter from the FDA clarifying that the FDA will not approve Phase 3 clinical testing of the Company’s EB-101 therapy until it provides “additional data points.” The price of Abeona Therapeutics stock fell following the announcement. If you purchased shares of Abeona Therapeutics and suffered a loss on that investment, you are encouraged to contact Marshall P. Dees, Esq. at mdees@holzerlaw.com or Luke R. Kennedy at lkennedy@holzerlaw.com, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.